Vicarious Surgical Inc. (RBOT) Stock Forecast & Price Target
Vicarious Surgical Inc. · NYSE
$0.04-0.01 (-13.56%)
15-min delayed · Sep 4, 3:00 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for RBOT yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $0.04 current
Highest Target—
Average Target—
Lowest Target—
RBOT analyst recommendation trends
86420
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Strong BuyBuyHoldSellStrong Sell
RATING
FEB
MAR
APR
MAY
JUN
JUL
Strong Buy
0
0
0
0
0
0
Buy
0
0
0
0
0
0
Hold
1
1
1
1
1
1
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Jul, 0 of 1 firms rate RBOT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RBOT EPS & revenue forecast
EPS · THIS QUARTER
$-1.20
Range $-1.20 – $-1.20 · 1 analysts · -53% YoY
Next period, 1 analysts expect Vicarious Surgical Inc. to earn $-1.20 a share (range $-1.20 – $-1.20), versus $-2.58 a year earlier. , growing to $-2.17 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $0, rising to $18.0M next year.
Top analysts covering Vicarious Surgical Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RBOT.
#1
Adam Maeder
Piper Sandler
Hold
$7.00+17894.9% to target
Coverage
—
+ Follow
#2
Ryan Zimmerman
BTIG
Hold
No targeton RBOT
Coverage
—
+ Follow
#3
JJ
Josh Jennings
TD Cowen
Buy
No targeton RBOT
Coverage
—
+ Follow
RBOT stock forecast FAQ
Who is the most accurate analyst covering RBOT?+
Among analysts who currently cover RBOT, Adam Maeder of Piper Sandler has the strongest overall Quantellect track record. Their current call is Hold with a $7.00 target.
What is Vicarious Surgical Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.20 per share (range $-1.20 – $-1.20) across 1 analysts. Full-year EPS is projected at —, rising to $-2.17 the following year.
How much revenue is Vicarious Surgical Inc. expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $0, growing to $18.0M next year.
Have analysts been upgrading or downgrading RBOT lately?+
As of Jul, 0 of 1 firms rate RBOT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RBOT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
